ES2571834T3 - Alquilsulfonamida quinolinas - Google Patents

Alquilsulfonamida quinolinas

Info

Publication number
ES2571834T3
ES2571834T3 ES06835833T ES06835833T ES2571834T3 ES 2571834 T3 ES2571834 T3 ES 2571834T3 ES 06835833 T ES06835833 T ES 06835833T ES 06835833 T ES06835833 T ES 06835833T ES 2571834 T3 ES2571834 T3 ES 2571834T3
Authority
ES
Spain
Prior art keywords
alkylsulfonamide
quinolines
quinolin
phenylpropyl
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06835833T
Other languages
English (en)
Inventor
Thomas Simpson
James Kang
Jeffrey Albert
Cristobal Alhambra
Gerard Koether
James Woods
Yan Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38163189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2571834(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2571834T3 publication Critical patent/ES2571834T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto que es 3-[(metilsulfonil)amino]-2-fenil-N-[(1S)-1-fenilpropil]quinolin-4-carboxamida o una de sus sales farmacéuticamente aceptable.
ES06835833T 2005-12-12 2006-12-11 Alquilsulfonamida quinolinas Active ES2571834T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74943105P 2005-12-12 2005-12-12
US82101606P 2006-08-01 2006-08-01
PCT/SE2006/001408 WO2007069977A1 (en) 2005-12-12 2006-12-11 Alkylsulphonamide quinolines

Publications (1)

Publication Number Publication Date
ES2571834T3 true ES2571834T3 (es) 2016-05-27

Family

ID=38163189

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06835833T Active ES2571834T3 (es) 2005-12-12 2006-12-11 Alquilsulfonamida quinolinas

Country Status (21)

Country Link
US (3) US7608628B2 (es)
EP (1) EP1968944B1 (es)
JP (1) JP5165581B2 (es)
KR (1) KR20080075867A (es)
AR (1) AR056890A1 (es)
AU (1) AU2006325572B2 (es)
BR (1) BRPI0619746A2 (es)
CA (1) CA2633129A1 (es)
DK (1) DK1968944T3 (es)
EC (1) ECSP088546A (es)
ES (1) ES2571834T3 (es)
HK (1) HK1121759A1 (es)
HU (1) HUE029805T2 (es)
IL (1) IL191628A0 (es)
NO (1) NO20083029L (es)
PL (1) PL1968944T3 (es)
PT (1) PT1968944T (es)
RU (1) RU2421447C2 (es)
TW (2) TW201018662A (es)
UY (1) UY30001A1 (es)
WO (1) WO2007069977A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018662A (en) * 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
CN102282139B (zh) * 2009-01-30 2014-06-18 弗·哈夫曼-拉罗切有限公司 作为nk3受体拮抗剂的哌啶衍生物
CN103619366B (zh) 2011-04-15 2018-02-16 马萨诸塞州大学 外科腔引流和闭合系统
EP4122626A1 (en) 2012-01-24 2023-01-25 Smith & Nephew, Inc. Porous structure and methods of making same
AU2014255512A1 (en) 2013-04-19 2015-11-12 Astrazeneca Ab A NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
GB201315846D0 (en) * 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
GB201503207D0 (en) 2015-02-26 2015-04-15 Univ Edinburgh Female health compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177096A (en) * 1989-10-25 1993-01-05 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles and pharmaceutical methods of use thereof
US5248689A (en) * 1989-11-06 1993-09-28 Smithkline Beecham Corporation Substituted N-(imidazolyl)alkyl alanine derivatives
NZ238688A (en) 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
HU226535B1 (en) * 1994-05-27 2009-03-30 Glaxosmithkline Spa Quinoline derivatives as tachykinin nk3 receptor antagonists, pharmaceutical compositions containing them, and their use
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
EP0934291A1 (en) 1995-10-30 1999-08-11 Smithkline Beecham Corporation Protease inhibitors
GB9524137D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
GB9524104D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
CN1207730A (zh) 1995-11-24 1999-02-10 史密丝克莱恩比彻姆股份公司 喹啉衍生物
EP0889888A4 (en) * 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
PE20000354A1 (es) 1998-04-03 2000-05-20 Advanced Medicine Inc Nuevos compuestos y usos anestesicos locales
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CN1406225A (zh) 1998-11-20 2003-03-26 葛兰素史密丝克莱恩有限公司 用作nk－3和nk－2受体拮抗剂的喹啉－4－甲酰胺衍生物
AU4802500A (en) * 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
CA2372233A1 (en) * 1999-05-27 2000-12-07 Pharmacia & Upjohn Company Bicyclic oxazolidinones as antibacterial agent
US6858630B2 (en) * 1999-12-06 2005-02-22 Smithkline Beecham Corporation Naphthimidazole derivatives and their use as thrombopoietin mimetics
US6248136B1 (en) * 2000-02-03 2001-06-19 Micell Technologies, Inc. Methods for carbon dioxide dry cleaning with integrated distribution
WO2002013825A1 (en) 2000-08-11 2002-02-21 Smithkline Beecham P.L.C. Novel pharmaceutical use of quinnoline derivatives
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
ATE399766T1 (de) 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
GB0027701D0 (en) * 2000-11-13 2000-12-27 Smithkline Beecham Spa Novel compounds
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
US20040006135A1 (en) 2002-06-19 2004-01-08 Pfizer Inc. Combination treatment for depression and anxiety
GB0228288D0 (en) 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0228287D0 (en) 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
US7459472B2 (en) 2003-08-08 2008-12-02 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
WO2005023771A1 (ja) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
WO2005094801A1 (en) 2004-03-25 2005-10-13 Smithkline Beecham Corporation Use of an nk3 antagonist for the treatment of bipolar disorders
EP1745019A1 (en) 2004-05-06 2007-01-24 Pfizer Inc. Novel compounds of proline and morpholine derivatives
GB0425077D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0509405D0 (en) 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
JP2008546767A (ja) * 2005-06-23 2008-12-25 アストラゼネカ・アクチエボラーグ Ｎｋ３受容体のモジュレーターとしてのキノリン３−スルホン酸エステル
CN101287723A (zh) * 2005-08-11 2008-10-15 阿斯利康(瑞典)有限公司 作为nk3受体调节剂的酰胺烷基吡啶基喹啉
WO2007022059A2 (en) 2005-08-12 2007-02-22 The Regents Of The University Of California Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
TW201018662A (en) * 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
EP1981882A4 (en) * 2006-01-27 2009-11-18 Astrazeneca Ab QUINOLINES SUBSTITUTED BY AN AMIDE
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina

Also Published As

Publication number Publication date
EP1968944A4 (en) 2011-01-12
PT1968944T (pt) 2016-07-29
JP2009519331A (ja) 2009-05-14
HUE029805T2 (en) 2017-03-28
US20100029717A1 (en) 2010-02-04
WO2007069977A1 (en) 2007-06-21
DK1968944T3 (en) 2016-08-01
CA2633129A1 (en) 2007-06-21
ECSP088546A (es) 2008-07-30
AU2006325572A1 (en) 2007-06-21
HK1121759A1 (zh) 2009-04-30
US20080021062A1 (en) 2008-01-24
US7608628B2 (en) 2009-10-27
US20080293765A1 (en) 2008-11-27
JP5165581B2 (ja) 2013-03-21
EP1968944B1 (en) 2016-04-20
US8071621B2 (en) 2011-12-06
KR20080075867A (ko) 2008-08-19
TW201018662A (en) 2010-05-16
AU2006325572B2 (en) 2011-02-24
AR056890A1 (es) 2007-10-31
UY30001A1 (es) 2007-07-31
NO20083029L (no) 2008-07-09
EP1968944A1 (en) 2008-09-17
RU2421447C2 (ru) 2011-06-20
TW200804288A (en) 2008-01-16
RU2008121761A (ru) 2010-01-20
PL1968944T3 (pl) 2016-11-30
BRPI0619746A2 (pt) 2011-10-11
IL191628A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
RS52681B (en) HYDROBENZOATE SALTS OF METHANICOTINE COMPOUND
ES2571834T3 (es) Alquilsulfonamida quinolinas
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
RS52931B (en) VIRAL POLYMERASE INHIBITORS
DE60323444D1 (de) Projektor
DE50202210D1 (de) Schnellverschlusskupplung
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
NL1024881A1 (nl) PPAR-activatoren.
IL166257A0 (en) Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors
DK1556377T3 (da) Cyclopropylthienylcarboxamider som fungicider
HN2003000071A (es) Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2
DE60326068D1 (de) Projektor
DK1499622T3 (da) Meterotricyclyl-6-alkylidenpenemer som beta-lactamaseinhibitorer
DE60331753D1 (de) Autonomer schmiermittelspender
NO20023191D0 (no) Projektor
DE60329649D1 (de) Reibschweissen
DE50302284D1 (de) Banner
UY29778A1 (es) Nueva asociación entre la agomelatina y un inhibidor de recaptura de noradrenalina y composiciones farmacéuticas que la contienen.
DK1485358T3 (da) Substitueret benzimidazol-sulfonamid som bred-sprektrum HIV-protease-inhibitorer
ITPR20040056A1 (it) Procedimento per valutare la sigillatura di un contenitore.
AR039253A1 (es) Asociacion de un antitrombotico y de aspirina
NL1026340A1 (nl) Beta-lactamaseremmerprodrug.
ZA200500926B (en) Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors
DE60213263D1 (de) Projektor
DE50310603D1 (de) Splittergeschoss